Evaxion biotech announces private placement financing

Copenhagen, denmark, dec. 19, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, is pleased to announce a private placement (the “private placement”) financing to raise gross proceeds of approximately $5.3 million. the private placement includes participation from existing and new shareholders, with the largest new shareholder being msd global health innovation fund (msd ghi), a corporate venture capital arm of merck & co., inc., rahway, nj, usa, accounting for some 25% of the total offering amount. further, the private placement includes significant participation by all members of the company's management and the company's board of directors.
EVAX Ratings Summary
EVAX Quant Ranking